Respiratory Therapeutics
1. Alvesco patent expiration
Treatment: Method of treating inflammatory conditions; Maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. patent claims method for treating a
ALVESCO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5775321 | COVIS | Seal configuration for aerosol canister |
Jul, 2015
(10 years ago) | |
| US5683677 | COVIS | Medicinal aerosol formulations |
Nov, 2014
(11 years ago) | |
| US5605674 | COVIS | Medicinal aerosol formulations |
Feb, 2014
(11 years ago) | |
| US6036942 | COVIS | Seal configuration for aerosol canister |
Apr, 2013
(12 years ago) | |
| US5482934 | COVIS | Pregna-1,4-diene3,20-dione-16-17-acetal-21 esters, process for their preparation, composition, and methods for the treatment of inflammatory conditions |
Oct, 2017
(8 years ago) | |
| US6264923 | COVIS | Medicinal aerosol formulation of ciclesonide and related compounds |
May, 2018
(7 years ago) | |
| US6006745 | COVIS | Device for delivering an aerosol |
Dec, 2016
(9 years ago) | |
| US6120752 | COVIS | Medicinal aerosol products containing formulations of ciclesonide and related steroids |
May, 2018
(7 years ago) | |
| US8371292 | COVIS | Use of ciclesonide for the treatment of respiratory diseases |
Feb, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 20, 2011 |
| M(M-125) | Dec 17, 2015 |
Drugs and Companies using CICLESONIDE ingredient
NCE-1 date: 20 October, 2010
Market Authorisation Date: 10 January, 2008
Dosage: AEROSOL, METERED
More Information on Dosage
ALVESCO family patents
2. Arcapta Neohaler patent expiration
Treatment: The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8658673 | NOVARTIS | BETA2-adrenoreceptor agonists |
Jun, 2020
(5 years ago) | |
| US8796307 | NOVARTIS | Beta2-adrenoreceptor agonists |
Jun, 2020
(5 years ago) | |
| US6878721 | NOVARTIS | Beta2-adrenoceptor agonists |
Feb, 2025
(10 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8067437 | NOVARTIS | Beta-2-adrenoreceptor agonists |
Jun, 2020
(5 years ago) | |
| US8479730 | NOVARTIS | Inhaler device |
Oct, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 01, 2016 |
Drugs and Companies using INDACATEROL MALEATE ingredient
NCE-1 date: 02 July, 2015
Market Authorisation Date: 01 July, 2011
Dosage: POWDER
More Information on Dosage
ARCAPTA NEOHALER family patents
3. Avelox patent
expiration
Treatment: Method of combating bacteria in a patient
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6610327 | BAYER HLTHCARE | Pharmaceutical moxifloxacin preparation |
Oct, 2019
(6 years ago) | |
| US5849752 | BAYER HLTHCARE | Crystal modification of CDCH a process for its preparation and pharmaceutical formulations comprising this modification |
Dec, 2016
(9 years ago) | |
| US5607942 | BAYER HLTHCARE | 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives |
Mar, 2014
(11 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-185) | Sep 27, 2019 |
Drugs and Companies using MOXIFLOXACIN HYDROCHLORIDE ingredient
Market Authorisation Date: 10 December, 1999
Dosage: TABLET
How can I launch a generic of AVELOX before it's drug patent expiration?
More Information on Dosage
AVELOX family patents
4. Chantix patent expiration
Treatment: Aid to smoking cessation
CHANTIX IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7265119 | PF PRISM CV | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Aug, 2022
(3 years ago) | |
|
US6410550 (Pediatric) | PF PRISM CV | Aryl fused azapolycyclic compounds |
Nov, 2020
(5 years ago) | |
|
US6890927 (Pediatric) | PF PRISM CV | Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Nov, 2022
(3 years ago) | |
|
US7265119 (Pediatric) | PF PRISM CV | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Feb, 2023
(2 years ago) | |
| US6410550 | PF PRISM CV | Aryl fused azapolycyclic compounds |
May, 2020
(5 years ago) | |
| US6890927 | PF PRISM CV | Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
May, 2022
(3 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-105) | Jul 22, 2014 |
| M(M-143) | Oct 15, 2017 |
| M(M-144) | Oct 15, 2017 |
| M(M-183) | Aug 12, 2019 |
| M(M-192) | Dec 16, 2019 |
| M(M-237) | Feb 22, 2022 |
| Pediatric Exclusivity(PED) | Aug 22, 2022 |
Drugs and Companies using VARENICLINE TARTRATE ingredient
Market Authorisation Date: 10 May, 2006
Dosage: TABLET
How can I launch a generic of CHANTIX before it's drug patent expiration?
More Information on Dosage
CHANTIX family patents
5. Clarinex patent expiration
Treatment: Treatment of chronic idiopathic urticaria; A method of treating nasal and non-nasal symptoms of seasonal allergic rhinitis; Treatment of allergic rhinitis; Administering desloratadine to treat the sym...
CLARINEX IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6100274 (Pediatric) | ORGANON | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
Jan, 2020
(6 years ago) | |
|
US7214684 (Pediatric) | ORGANON | Methods for the treatment of allergic rhinitis |
Jun, 2015
(10 years ago) | |
|
US5607697 (Pediatric) | ORGANON | Taste masking microparticles for oral dosage forms |
Dec, 2015
(10 years ago) | |
| US7211582 | ORGANON | Methods for treating urticaria using descarboethoxyloratadine |
Dec, 2014
(11 years ago) | |
| US7618649 | ORGANON | Extended release oral dosage composition |
Dec, 2020
(5 years ago) | |
| US7214684 | ORGANON | Methods for the treatment of allergic rhinitis |
Dec, 2014
(11 years ago) | |
| US7214683 | ORGANON | Compositions of descarboethoxyloratadine |
Dec, 2014
(11 years ago) | |
| US5607697 | ORGANON | Taste masking microparticles for oral dosage forms |
Jun, 2015
(10 years ago) | |
| US6100274 | ORGANON | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
Jul, 2019
(6 years ago) | |
|
US7214683 (Pediatric) | ORGANON | Compositions of descarboethoxyloratadine |
Jun, 2015
(10 years ago) | |
|
US7211582 (Pediatric) | ORGANON | Methods for treating urticaria using descarboethoxyloratadine |
Jun, 2015
(10 years ago) | |
|
US7618649 (Pediatric) | ORGANON | Extended release oral dosage composition |
Jun, 2021
(4 years ago) | |
|
US7405223 (Pediatric) | ORGANON | Treating allergic and inflammatory conditions |
Jan, 2020
(6 years ago) | |
| US7405223 | ORGANON | Treating allergic and inflammatory conditions |
Jul, 2019
(6 years ago) | |
Drugs and Companies using DESLORATADINE ingredient
Market Authorisation Date: 14 July, 2005
Dosage: TABLET, ORALLY DISINTEGRATING; TABLET
How can I launch a generic of CLARINEX before it's drug patent expiration?
More Information on Dosage
CLARINEX family patents
6. Clarinex patent expiration
Treatment: Treatment of allergic rhinitis; Treatment of chronic idiopathic urticaria
CLARINEX IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6514520 | MERCK SHARP DOHME | Stabilized antihistamine syrup |
Jun, 2018
(7 years ago) | |
| US7214684 | MERCK SHARP DOHME | Methods for the treatment of allergic rhinitis |
Dec, 2014
(11 years ago) | |
| US7214683 | MERCK SHARP DOHME | Compositions of descarboethoxyloratadine |
Dec, 2014
(11 years ago) | |
| US7211582 | MERCK SHARP DOHME | Methods for treating urticaria using descarboethoxyloratadine |
Dec, 2014
(11 years ago) | |
|
US7214684 (Pediatric) | MERCK SHARP DOHME | Methods for the treatment of allergic rhinitis |
Jun, 2015
(10 years ago) | |
|
US7214683 (Pediatric) | MERCK SHARP DOHME | Compositions of descarboethoxyloratadine |
Jun, 2015
(10 years ago) | |
|
US7211582 (Pediatric) | MERCK SHARP DOHME | Methods for treating urticaria using descarboethoxyloratadine |
Jun, 2015
(10 years ago) | |
|
US6514520 (Pediatric) | MERCK SHARP DOHME | Stabilized antihistamine syrup |
Dec, 2018
(7 years ago) | |
Drugs and Companies using DESLORATADINE ingredient
Market Authorisation Date: 01 September, 2004
Dosage: SOLUTION
How can I launch a generic of CLARINEX before it's drug patent expiration?
More Information on Dosage
CLARINEX family patents
7. Daliresp patent expiration
Treatment: Treatment to reduce the risk of copd exacerbations in patients with severe copd associated with chronic bronchitis and a history of exacerbations
DALIRESP's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5712298 | ASTRAZENECA | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
Jan, 2020
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8536206 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(1 year, 10 months ago) | |
| US8431154 | ASTRAZENECA | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient |
Feb, 2023
(2 years ago) | |
| US9468598 | ASTRAZENECA | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
Feb, 2023
(2 years ago) | |
| US5712298 | ASTRAZENECA | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
Jan, 2015
(10 years ago) | |
| US8604064 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(1 year, 10 months ago) | |
| US8618142 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(1 year, 10 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 28, 2016 |
| M(M-208) | Aug 31, 2020 |
| New Dosing Schedule(D-171) | Jan 23, 2021 |
| New Strength(NS) | Jan 23, 2021 |
Drugs and Companies using ROFLUMILAST ingredient
NCE-1 date: 28 February, 2015
Market Authorisation Date: 23 January, 2018
Dosage: TABLET
How can I launch a generic of DALIRESP before it's drug patent expiration?
More Information on Dosage
DALIRESP family patents
8. Esbriet patent expiration
Treatment: Pirfenidone dose escalation regimen for treatment of fibrosis as 801 mg/day for days 1-7 of the regimen, 1602 mg/day for days 8-14 of the regimen, and 2403 mg/day for at least day 15 of the regimen; D...
ESBRIET's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8420674 | LEGACY PHARMA | Method of providing pirfenidone therapy to a patient |
Dec, 2027
(1 year, 11 months from now) | |
| US7696326 | LEGACY PHARMA | Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof |
Dec, 2027
(1 year, 11 months from now) | |
| US9561217 | LEGACY PHARMA | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone |
Jan, 2022
(3 years ago) | |
| US7696236 | LEGACY PHARMA | Method of providing pirfenidone therapy to a patient |
Dec, 2027
(1 year, 11 months from now) | |
| US7988994 | LEGACY PHARMA | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep, 2026
(8 months from now) | |
| US8013002 | LEGACY PHARMA | Methods of administering pirfenidone therapy |
Jan, 2030
(3 years from now) | |
| US8778947 | LEGACY PHARMA | Methods of administering pirfenidone therapy |
Aug, 2033
(7 years from now) | |
| US7767225 | LEGACY PHARMA | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep, 2026
(8 months from now) | |
| US7767700 | LEGACY PHARMA | Method of providing pirfenidone therapy to a patient |
Dec, 2027
(1 year, 11 months from now) | |
| US7816383 | LEGACY PHARMA | Methods of administering pirfenidone therapy |
Jan, 2030
(3 years from now) | |
| US8754109 | LEGACY PHARMA | Pirfenidone therapy and inducers of cytochrome P450 |
Jan, 2030
(3 years from now) | |
| US8318780 | LEGACY PHARMA | Methods of administering pirfenidone therapy |
Jan, 2030
(3 years from now) | |
| US7910610 | LEGACY PHARMA | Methods of administering pirfenidone therapy |
Jan, 2030
(3 years from now) | |
| US7566729 | LEGACY PHARMA | Modifying pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(3 years from now) | |
| US8383150 | LEGACY PHARMA | Granulate formulation of pirfenidone and pharmaceutically acceptable excipients |
May, 2028
(2 years from now) | |
| US8084475 | LEGACY PHARMA | Pirfenidone therapy and inducers of cytochrome P450 |
Jan, 2030
(3 years from now) | |
| US8592462 | LEGACY PHARMA | Pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(3 years from now) | |
| US8753679 | LEGACY PHARMA | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep, 2026
(8 months from now) | |
| US8609701 | LEGACY PHARMA | Pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(3 years from now) | |
| US8648098 | LEGACY PHARMA | Pirfenidone therapy and inducers of cytochrome P450 |
Jan, 2030
(3 years from now) | |
| US7635707 | LEGACY PHARMA | Pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(3 years from now) | |
| US10188637 | LEGACY PHARMA | Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same |
Mar, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 15, 2019 |
| Orphan Drug Exclusivity(ODE) | Oct 15, 2021 |
| Orphan Drug Exclusivity(ODE-77) | Oct 15, 2021 |
Drugs and Companies using PIRFENIDONE ingredient
NCE-1 date: 15 October, 2018
Market Authorisation Date: 15 October, 2014
Dosage: TABLET
How can I launch a generic of ESBRIET before it's drug patent expiration?
More Information on Dosage
ESBRIET family patents
9. Factive patent expiration
Treatment: Method of treating bacterial infections; Use of quinolone compounds against anaerobic pathogenic bacteria; Use of quinolone compounds against pneumococcal pathogenic bacteria; Use of quinolone compoun...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5962468 | LG CHEM LTD | 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1- cyclopropyl-6-fluoro-4-oxo-1, 4-dihydro-1, 8-naphthyridine-3-carboxylic acid and the process for the preparation thereof |
Jun, 2015
(10 years ago) | |
| US6455540 | LG CHEM LTD | Methods of use of quinolone compounds against anaerobic pathogenic bacteria |
Sep, 2019
(6 years ago) | |
| US5633262 | LG CHEM LTD | Quinoline carboxylic acid derivatives having 7-(4-amino-methyl-3-oxime) pyrrolidine substituent and processes for preparing thereof |
Jun, 2015
(10 years ago) | |
| US6803376 | LG CHEM LTD | Method of use of quinolone compounds against pneumococcal and haemophilus bacteria |
Sep, 2019
(6 years ago) | |
| US6340689 | LG CHEM LTD | Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria |
Sep, 2019
(6 years ago) | |
| US5776944 | LG CHEM LTD | 7-(4-aminomethyl-3-methyloxyiminopyrroplidin-1-yl)-1-cyclopropyl-6-flu oro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid and the process for the preparation thereof |
Apr, 2017
(8 years ago) | |
| US6723734 | LG CHEM LTD | Salt of naphthyridine carboxylic acid derivative |
Mar, 2018
(7 years ago) | |
| US6331550 | LG CHEM LTD | Methods of use of quinolone compounds against anaerobic pathogenic bacteria |
Sep, 2019
(6 years ago) | |
| US6262071 | LG CHEM LTD | Methods of use of antimicrobial compounds against pathogenic amycoplasma bacteria |
Sep, 2019
(6 years ago) | |
Drugs and Companies using GEMIFLOXACIN MESYLATE ingredient
Market Authorisation Date: 04 April, 2003
Dosage: TABLET
How can I launch a generic of FACTIVE before it's drug patent expiration?
More Information on Dosage
FACTIVE family patents
10. Inomax patent expiration
Treatment: A method of providing nitric oxide therapy to a patient; A method of purging a nitric oxide delivery system; Prevention or treatment of reversible vasoconstriction by the inhalation of nitric oxide wi...
INOMAX IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11931377 | MALLINCKRODT IRELAND | Methods of administering inhaled nitric oxide gas |
Jun, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6125846 (Pediatric) | MALLINCKRODT IRELAND | Purge system for nitric oxide administration apparatus |
Nov, 2017
(8 years ago) | |
| US5732693 | MALLINCKRODT IRELAND | Pause control of nitric oxide therapy |
Dec, 2016
(9 years ago) | |
| US5752504 | MALLINCKRODT IRELAND | System for monitoring therapy during calibration |
Dec, 2016
(9 years ago) | |
| US6125846 | MALLINCKRODT IRELAND | Purge system for nitric oxide administration apparatus |
May, 2017
(8 years ago) | |
|
US5485827 (Pediatric) | MALLINCKRODT IRELAND | Methods and devices for treating plumonary vasoconstriction and asthma |
Jul, 2013
(12 years ago) | |
|
US5558083 (Pediatric) | MALLINCKRODT IRELAND | Nitric oxide delivery system |
May, 2014
(11 years ago) | |
|
US5873359 (Pediatric) | MALLINCKRODT IRELAND | Methods and devices for treating pulmonary vasoconstriction and asthma |
Jul, 2013
(12 years ago) | |
| US5873359 | MALLINCKRODT IRELAND | Methods and devices for treating pulmonary vasoconstriction and asthma |
Jan, 2013
(12 years ago) | |
|
US5752504 (Pediatric) | MALLINCKRODT IRELAND | System for monitoring therapy during calibration |
Jun, 2017
(8 years ago) | |
|
US5732693 (Pediatric) | MALLINCKRODT IRELAND | Pause control of nitric oxide therapy |
Jun, 2017
(8 years ago) | |
| US8776795 | MALLINCKRODT IRELAND | Gas delivery device and system |
Jan, 2031
(4 years from now) | |
| US8573210 | MALLINCKRODT IRELAND | Nitric oxide delivery device |
Jan, 2031
(4 years from now) | |
| US5558083 | MALLINCKRODT IRELAND | Nitric oxide delivery system |
Nov, 2013
(12 years ago) | |
| US5485827 | MALLINCKRODT IRELAND | Methods and devices for treating plumonary vasoconstriction and asthma |
Jan, 2013
(12 years ago) | |
| US9265911 | MALLINCKRODT IRELAND | Gas delivery device and system |
Jan, 2031
(4 years from now) | |
| US9295802 | MALLINCKRODT IRELAND | Gas delivery device and system |
Jan, 2031
(4 years from now) | |
| US8282966 | MALLINCKRODT IRELAND | Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide |
Jun, 2029
(3 years from now) | |
| US8293284 | MALLINCKRODT IRELAND | Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide |
Jun, 2029
(3 years from now) | |
| US8291904 | MALLINCKRODT IRELAND | Gas delivery device and system |
Jan, 2031
(4 years from now) | |
| US8846112 | MALLINCKRODT IRELAND | Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation |
Jun, 2029
(3 years from now) | |
| US8776794 | MALLINCKRODT IRELAND | Nitric oxide delivery device |
Jan, 2031
(4 years from now) | |
| US8795741 | MALLINCKRODT IRELAND | Methods for treating patients who are candidates for inhaled nitric oxide treatment |
Jun, 2029
(3 years from now) | |
| US9279794 | MALLINCKRODT IRELAND | Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide |
Feb, 2035
(9 years from now) | |
| US8431163 | MALLINCKRODT IRELAND | Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas |
Jun, 2029
(3 years from now) | |
| US9408993 | MALLINCKRODT IRELAND | Nitric oxide delivery device |
Jan, 2031
(4 years from now) | |
| US9770570 | MALLINCKRODT IRELAND | Apparatus and method for monitoring nitric oxide delivery |
May, 2036
(10 years from now) | |
| US8573209 | MALLINCKRODT IRELAND | Gas delivery device and system |
Jan, 2031
(4 years from now) | |
|
US8282966 (Pediatric) | MALLINCKRODT IRELAND | Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide |
Dec, 2029
(3 years from now) | |
|
US8291904 (Pediatric) | MALLINCKRODT IRELAND | Gas delivery device and system |
Jul, 2031
(5 years from now) | |
|
US8293284 (Pediatric) | MALLINCKRODT IRELAND | Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide |
Dec, 2029
(3 years from now) | |
|
US8431163 (Pediatric) | MALLINCKRODT IRELAND | Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas |
Dec, 2029
(3 years from now) | |
|
US8776795 (Pediatric) | MALLINCKRODT IRELAND | Gas delivery device and system |
Jul, 2031
(5 years from now) | |
|
US8776794 (Pediatric) | MALLINCKRODT IRELAND | Nitric oxide delivery device |
Jul, 2031
(5 years from now) | |
|
US8795741 (Pediatric) | MALLINCKRODT IRELAND | Methods for treating patients who are candidates for inhaled nitric oxide treatment |
Dec, 2029
(3 years from now) | |
|
US8573209 (Pediatric) | MALLINCKRODT IRELAND | Gas delivery device and system |
Jul, 2031
(5 years from now) | |
|
US8846112 (Pediatric) | MALLINCKRODT IRELAND | Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation |
Dec, 2029
(3 years from now) | |
|
US8573210 (Pediatric) | MALLINCKRODT IRELAND | Nitric oxide delivery device |
Jul, 2031
(5 years from now) | |
|
US9295802 (Pediatric) | MALLINCKRODT IRELAND | Gas delivery device and system |
Jul, 2031
(5 years from now) | |
|
US9408993 (Pediatric) | MALLINCKRODT IRELAND | Nitric oxide delivery device |
Jul, 2031
(5 years from now) | |
|
US9265911 (Pediatric) | MALLINCKRODT IRELAND | Gas delivery device and system |
Jul, 2031
(5 years from now) | |
|
US9279794 (Pediatric) | MALLINCKRODT IRELAND | Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide |
Aug, 2035
(9 years from now) | |
|
US11931377 (Pediatric) | MALLINCKRODT IRELAND | Methods of administering inhaled nitric oxide gas |
Dec, 2029
(3 years from now) | |
|
US9770570 (Pediatric) | MALLINCKRODT IRELAND | Apparatus and method for monitoring nitric oxide delivery |
Nov, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-132) | Dec 21, 2013 |
| Pediatric Exclusivity(PED) | Jun 21, 2014 |
| M(M-167) | Oct 09, 2018 |
Drugs and Companies using NITRIC OXIDE ingredient
Market Authorisation Date: 23 December, 1999
Dosage: GAS
How can I launch a generic of INOMAX before it's drug patent expiration?
More Information on Dosage
INOMAX family patents
11. Kalydeco patent expiration
Treatment: Treatment of cf in a patient age 1 month to less than 6 years old who has in the cftr gene at least one mutation responsive to iva based on clinical and/or in vitro assay data using the composition re...
KALYDECO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7495103 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(1 year, 4 months from now) | |
| US8754224 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8410274 (Pediatric) | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Jun, 2027
(1 year, 5 months from now) | |
|
US8354427 (Pediatric) | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jan, 2027
(11 months from now) | |
|
US8324242 (Pediatric) | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Feb, 2028
(2 years from now) | |
|
US8754224 (Pediatric) | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Jun, 2027
(1 year, 5 months from now) | |
|
US8883206 (Pediatric) | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2033
(7 years from now) | |
|
US7495103 (Pediatric) | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Nov, 2027
(1 year, 10 months from now) | |
|
US9670163 (Pediatric) | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Jun, 2027
(1 year, 5 months from now) | |
|
US10272046 (Pediatric) | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2033
(7 years from now) | |
|
US10646481 (Pediatric) | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2030
(4 years from now) | |
|
US11147770 (Pediatric) | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2033
(7 years from now) | |
|
US11752106 (Pediatric) | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2033
(7 years from now) | |
|
US12214083 (Pediatric) | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2033
(7 years from now) | |
|
US11564916 (Pediatric) | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2030
(4 years from now) | |
|
US12458635 (Pediatric) | VERTEX PHARMS INC | NA |
Feb, 2030
(4 years from now) | |
| US12458635 | VERTEX PHARMS INC | NA |
Aug, 2029
(3 years from now) | |
| US9670163 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(11 months from now) | |
| US8629162 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jun, 2025
(6 months ago) | |
| US8354427 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jul, 2026
(5 months from now) | |
| US11147770 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(7 years from now) | |
| US11564916 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(3 years from now) | |
| US12214083 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(7 years from now) | |
| US8324242 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Aug, 2027
(1 year, 6 months from now) | |
| US10272046 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(7 years from now) | |
| US11752106 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(7 years from now) | |
| US8883206 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(7 years from now) | |
| US10646481 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(3 years from now) | |
| US8410274 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2017 |
| New Indication(I-740) | Feb 21, 2017 |
| New Indication(I-705) | Dec 30, 2017 |
| Orphan Drug Exclusivity(ODE) | Jan 31, 2019 |
| Orphan Drug Exclusivity(ODE-20) | Jan 31, 2019 |
| New Patient Population(NPP) | May 03, 2026 |
| Orphan Drug Exclusivity(ODE-186) | Feb 21, 2021 |
| Orphan Drug Exclusivity(ODE-187) | Dec 29, 2021 |
| Orphan Drug Exclusivity(ODE-188) | Mar 17, 2022 |
| Orphan Drug Exclusivity(ODE-190) | May 17, 2024 |
| Orphan Drug Exclusivity(ODE-189) | Jul 31, 2024 |
| Orphan Drug Exclusivity(ODE-199) | Aug 15, 2025 |
| Orphan Drug Exclusivity(ODE-236) | Apr 29, 2026 |
| Orphan Drug Exclusivity(ODE-338) | Dec 21, 2027 |
| M(M-14) | May 22, 2028 |
| Pediatric Exclusivity(PED) | Nov 22, 2028 |
| Orphan Drug Exclusivity(ODE-435) | May 03, 2030 |
Drugs and Companies using IVACAFTOR ingredient
NCE-1 date: 23 November, 2027
Market Authorisation Date: 03 May, 2023
Dosage: GRANULE
How can I launch a generic of KALYDECO before it's drug patent expiration?
More Information on Dosage
KALYDECO family patents
12. Kalydeco patent expiration
Treatment: Method of treating cystic fibrosis; Treatment of cf in a patient age 6 years and older who has in the cftr gene at least one mutation responsive to iva based on clinical and/or in vitro assay data usi...
KALYDECO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8754224 | VERTEX PHARMS | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(11 months from now) | |
| US7495103 | VERTEX PHARMS | Modulators of ATP-binding cassette transporters |
May, 2027
(1 year, 4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9670163 | VERTEX PHARMS | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(11 months from now) | |
| US12458635 | VERTEX PHARMS | NA |
Aug, 2029
(3 years from now) | |
| US8629162 | VERTEX PHARMS | Modulators of ATP-binding cassette transporters |
Jun, 2025
(6 months ago) | |
| US11564916 | VERTEX PHARMS | Pharmaceutical composition and administrations thereof |
Aug, 2029
(3 years from now) | |
| US8324242 | VERTEX PHARMS | Modulators of ATP-binding cassette transporters |
Aug, 2027
(1 year, 6 months from now) | |
| US8354427 | VERTEX PHARMS | Modulators of ATP-binding cassette transporters |
Jul, 2026
(5 months from now) | |
| US8410274 | VERTEX PHARMS | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(11 months from now) | |
| US10646481 | VERTEX PHARMS | Pharmaceutical composition and administrations thereof |
Aug, 2029
(3 years from now) | |
|
US7495103 (Pediatric) | VERTEX PHARMS | Modulators of ATP-binding cassette transporters |
Nov, 2027
(1 year, 10 months from now) | |
|
US8324242 (Pediatric) | VERTEX PHARMS | Modulators of ATP-binding cassette transporters |
Feb, 2028
(2 years from now) | |
|
US8410274 (Pediatric) | VERTEX PHARMS | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Jun, 2027
(1 year, 5 months from now) | |
|
US8754224 (Pediatric) | VERTEX PHARMS | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Jun, 2027
(1 year, 5 months from now) | |
|
US8354427 (Pediatric) | VERTEX PHARMS | Modulators of ATP-binding cassette transporters |
Jan, 2027
(11 months from now) | |
|
US9670163 (Pediatric) | VERTEX PHARMS | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Jun, 2027
(1 year, 5 months from now) | |
|
US10646481 (Pediatric) | VERTEX PHARMS | Pharmaceutical composition and administrations thereof |
Feb, 2030
(4 years from now) | |
|
US12458635 (Pediatric) | VERTEX PHARMS | NA |
Feb, 2030
(4 years from now) | |
|
US11564916 (Pediatric) | VERTEX PHARMS | Pharmaceutical composition and administrations thereof |
Feb, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2017 |
| New Indication(I-740) | Feb 21, 2017 |
| New Indication(I-705) | Dec 30, 2017 |
| Orphan Drug Exclusivity(ODE) | Jan 31, 2019 |
| Orphan Drug Exclusivity(ODE-20) | Jan 31, 2019 |
| New Patient Population(NPP) | May 03, 2026 |
| Orphan Drug Exclusivity(ODE-186) | Feb 21, 2021 |
| Orphan Drug Exclusivity(ODE-187) | Dec 29, 2021 |
| Orphan Drug Exclusivity(ODE-188) | Mar 17, 2022 |
| Orphan Drug Exclusivity(ODE-190) | May 17, 2024 |
| Orphan Drug Exclusivity(ODE-189) | Jul 31, 2024 |
| Orphan Drug Exclusivity(ODE-199) | Aug 15, 2025 |
| Orphan Drug Exclusivity(ODE-236) | Apr 29, 2026 |
| Orphan Drug Exclusivity(ODE-338) | Dec 21, 2027 |
| M(M-14) | May 22, 2028 |
| Pediatric Exclusivity(PED) | Nov 22, 2028 |
| Orphan Drug Exclusivity(ODE-435) | May 03, 2030 |
Drugs and Companies using IVACAFTOR ingredient
NCE-1 date: 22 June, 2027
Market Authorisation Date: 20 May, 2019
Dosage: TABLET
How can I launch a generic of KALYDECO before it's drug patent expiration?
More Information on Dosage
KALYDECO family patents
13. Modeyso patent expiration
Treatment: Method of treating adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an h3 k27m mutation with progressive disease following prior therapy
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12102639 | CHIMERIX | NA |
Jan, 2037
(11 years from now) | |
| US10369154 | CHIMERIX | NA |
Jan, 2037
(11 years from now) | |
| US10172862 | CHIMERIX | NA |
Jan, 2037
(11 years from now) | |
| US9629842 | CHIMERIX | NA |
Apr, 2032
(6 years from now) | |
| USRE46290 | CHIMERIX | NA |
Apr, 2032
(6 years from now) | |
| US11976068 | CHIMERIX | NA |
Mar, 2036
(10 years from now) | |
| US9265765 | CHIMERIX | NA |
Jul, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 06, 2030 |
Drugs and Companies using DORDAVIPRONE HYDROCHLORIDE ingredient
NCE-1 date: 06 August, 2029
Market Authorisation Date: 06 August, 2025
Dosage: CAPSULE
More Information on Dosage
MODEYSO family patents
14. Ofev patent expiration
Treatment: Treatment of idiopathic pulmonary fibrosis (ipf); Use of nintedanib for slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (ssc-...
OFEV's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7119093 | BOEHRINGER INGELHEIM | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition |
Feb, 2024
(1 year, 10 months ago) | |
| US6762180 | BOEHRINGER INGELHEIM | Substituted indolines which inhibit receptor tyrosine kinases |
Oct, 2025
(3 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7989474 | BOEHRINGER INGELHEIM | Use of Lck inhibitors for treatment of immunologic diseases |
Apr, 2024
(1 year, 9 months ago) | |
| US10154990 | BOEHRINGER INGELHEIM | Medicaments for the treatment or prevention of fibrotic diseases |
Jan, 2026
(a day ago) | |
| US9907756 | BOEHRINGER INGELHEIM | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative |
Jun, 2029
(3 years from now) | |
| US10105323 | BOEHRINGER INGELHEIM | Pharmaceutical dosage form for immediate release of an indolinone derivative |
Jun, 2029
(3 years from now) | |
|
US6762180 (Pediatric) | BOEHRINGER INGELHEIM | Substituted indolines which inhibit receptor tyrosine kinases |
Apr, 2026
(2 months from now) | |
|
US9907756 (Pediatric) | BOEHRINGER INGELHEIM | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative |
Dec, 2029
(3 years from now) | |
|
US10105323 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical dosage form for immediate release of an indolinone derivative |
Dec, 2029
(3 years from now) | |
|
US10154990 (Pediatric) | BOEHRINGER INGELHEIM | Medicaments for the treatment or prevention of fibrotic diseases |
Jul, 2026
(5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 15, 2019 |
| Orphan Drug Exclusivity(ODE) | Oct 15, 2021 |
| Orphan Drug Exclusivity(ODE-77) | Oct 15, 2021 |
| New Indication(I-805) | Sep 06, 2022 |
| New Indication(I-825) | Mar 09, 2023 |
| Orphan Drug Exclusivity(ODE-261) | Sep 06, 2026 |
| Pediatric Exclusivity(PED) | Mar 06, 2027 |
Drugs and Companies using NINTEDANIB ESYLATE ingredient
NCE-1 date: 06 March, 2026
Market Authorisation Date: 15 October, 2014
Dosage: CAPSULE
How can I launch a generic of OFEV before it's drug patent expiration?
More Information on Dosage
OFEV family patents
15. Ohtuvayre patent expiration
Treatment: For the maintenance treatment of chronic obstructive pulmonary disease (copd) in adult patients
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9062047 | VERONA PHARMA | Crystalline form of pyrimido[6,1-A] isoquinolin-4-one compound |
Aug, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9956171 | VERONA PHARMA | Liquid inhalation formulation comprising RPL554 |
Sep, 2035
(9 years from now) | |
| US12251384 | VERONA PHARMA | Particulate composition |
Jun, 2044
(18 years from now) | |
| US12409180 | VERONA PHARMA | NA |
Feb, 2043
(17 years from now) | |
| US10945950 | VERONA PHARMA | Liquid inhalation formulation comprising RPL554 |
Sep, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 26, 2029 |
Drugs and Companies using ENSIFENTRINE ingredient
NCE-1 date: 26 June, 2028
Market Authorisation Date: 26 June, 2024
Dosage: SUSPENSION
More Information on Dosage
OHTUVAYRE family patents
16. Olumiant patent expiration
Treatment: Treatment of adult patients with severe alopecia areata; Treatment of coronavirus disease 2019 (covid-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical vent...
OLUMIANT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8158616 | ELI LILLY AND CO | Azetidine and cyclobutane derivatives as JAK inhibitors |
May, 2032
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9737469 | ELI LILLY AND CO | Methods for treating hair loss disorders |
Nov, 2031
(5 years from now) | |
| US9089574 | ELI LILLY AND CO | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
Nov, 2032
(6 years from now) | |
| US11045474 | ELI LILLY AND CO | Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections |
Nov, 2032
(6 years from now) | |
| US8420629 | ELI LILLY AND CO | Azetidine and cyclobutane derivatives as JAK inhibitors |
Mar, 2029
(3 years from now) | |
| US11806555 | ELI LILLY AND CO | Methods for treating hair loss disorders |
Nov, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 31, 2023 |
| New Indication(I-891) | May 10, 2025 |
| New Indication(I-890) | Jun 13, 2025 |
Drugs and Companies using BARICITINIB ingredient
NCE-1 date: 31 May, 2022
Market Authorisation Date: 08 October, 2019
Dosage: TABLET
How can I launch a generic of OLUMIANT before it's drug patent expiration?
More Information on Dosage
OLUMIANT family patents
17. Omnaris patent expiration
Treatment: Nasal treatment of seasonal and perennial allergic rhinitis symptoms; Treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. treatment ...
OMNARIS's oppositions filed in EPO
OMNARIS IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5482934 | COVIS | Pregna-1,4-diene3,20-dione-16-17-acetal-21 esters, process for their preparation, composition, and methods for the treatment of inflammatory conditions |
Oct, 2017
(8 years ago) | |
| US7235247 | COVIS | Pharmaceutical composition for application to mucosa |
Apr, 2019
(6 years ago) | |
| US6767901 | COVIS | Ciclesonide contained pharmaceutical composition for application to mucosa |
Oct, 2020
(5 years ago) | |
| US6939559 | COVIS | Pharmaceutical composition for application to mucosa |
Apr, 2019
(6 years ago) | |
| US8383611 | COVIS | Ciclesonide containing aqueous pharmaceutical composition |
Oct, 2020
(5 years ago) | |
| US8371292 | COVIS | Use of ciclesonide for the treatment of respiratory diseases |
Feb, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 20, 2011 |
Drugs and Companies using CICLESONIDE ingredient
NCE-1 date: 20 October, 2010
Market Authorisation Date: 20 October, 2006
Dosage: SPRAY, METERED
How can I launch a generic of OMNARIS before it's drug patent expiration?
More Information on Dosage
OMNARIS family patents
18. Rapamune patent expiration
Treatment: Inhibiting transplant rejection using rapamycin (sirolimus)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5536729 | PF PRISM CV | Rapamycin formulations for oral administration |
Sep, 2013
(12 years ago) | |
| US5100899 | PF PRISM CV | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
Jul, 2013
(12 years ago) | |
| US5989591 | PF PRISM CV | Rapamycin formulations for oral administration |
Mar, 2018
(7 years ago) | |
|
US5536729 (Pediatric) | PF PRISM CV | Rapamycin formulations for oral administration |
Mar, 2014
(11 years ago) | |
|
US5100899 (Pediatric) | PF PRISM CV | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
Jan, 2014
(12 years ago) | |
|
US5403833 (Pediatric) | PF PRISM CV | Methods of inhibiting transplant rejecton in mammals using rapamycin and derivatives and prodrugs thereof |
Oct, 2012
(13 years ago) | |
|
US5989591 (Pediatric) | PF PRISM CV | Rapamycin formulations for oral administration |
Sep, 2018
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | May 28, 2022 |
| Orphan Drug Exclusivity(ODE-92) | May 28, 2022 |
Drugs and Companies using SIROLIMUS ingredient
Market Authorisation Date: 15 September, 1999
Dosage: SOLUTION; TABLET
How can I launch a generic of RAPAMUNE before it's drug patent expiration?
More Information on Dosage
RAPAMUNE family patents
19. Rebetol patent expiration
Treatment: Method of using ribavirin in combination with pegylated interferon alpha-2b to treat patients with chronic hepatitis c; Method of using ribavirin in combination with intron a (interferon alpha-2 b rec...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6524570 | SCHERING | Polyethylene glycol modified interferon therapy |
Nov, 2016
(9 years ago) | |
|
US6524570 (Pediatric) | SCHERING | Polyethylene glycol modified interferon therapy |
May, 2017
(8 years ago) | |
| US6472373 | SCHERING | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Sep, 2017
(8 years ago) | |
| US6461605 | SCHERING | Continuous low-dose cytokine infusion therapy |
Nov, 2016
(9 years ago) | |
| US6177074 | SCHERING | Polyethylene glycol modified interferon therapy |
Nov, 2016
(9 years ago) | |
| US6790837 | SCHERING | Ribavirin syrup formulations |
Apr, 2023
(2 years ago) | |
|
US6790837 (Pediatric) | SCHERING | Ribavirin syrup formulations |
Oct, 2023
(2 years ago) | |
|
US6461605 (Pediatric) | SCHERING | Continuous low-dose cytokine infusion therapy |
May, 2017
(8 years ago) | |
|
US6177074 (Pediatric) | SCHERING | Polyethylene glycol modified interferon therapy |
May, 2017
(8 years ago) | |
|
US6172046 (Pediatric) | SCHERING | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Mar, 2018
(7 years ago) | |
| US6172046 | SCHERING | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Sep, 2017
(8 years ago) | |
|
US6472373 (Pediatric) | SCHERING | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Mar, 2018
(7 years ago) | |
Drugs and Companies using RIBAVIRIN ingredient
Market Authorisation Date: 29 July, 2003
Dosage: SOLUTION
How can I launch a generic of REBETOL before it's drug patent expiration?
More Information on Dosage
REBETOL family patents
20. Rebetol patent expiration
Treatment: Method of tx a pt suspected of having hepatitis c by admin, in combination, a conjugate comprising peg 12000 & interferon alfa-2b in an amt of from 0.5mcg/kg to 2mcg/kg, once weekly, and ribavirin; Me...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6177074 (Pediatric) | MERCK SHARP DOHME | Polyethylene glycol modified interferon therapy |
May, 2017
(8 years ago) | |
|
US6524570 (Pediatric) | MERCK SHARP DOHME | Polyethylene glycol modified interferon therapy |
May, 2017
(8 years ago) | |
| US6472373 | MERCK SHARP DOHME | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Sep, 2017
(8 years ago) | |
| US6172046 | MERCK SHARP DOHME | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Sep, 2017
(8 years ago) | |
| US6461605 | MERCK SHARP DOHME | Continuous low-dose cytokine infusion therapy |
Nov, 2016
(9 years ago) | |
|
US6172046 (Pediatric) | MERCK SHARP DOHME | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Mar, 2018
(7 years ago) | |
| US6177074 | MERCK SHARP DOHME | Polyethylene glycol modified interferon therapy |
Nov, 2016
(9 years ago) | |
|
US6472373 (Pediatric) | MERCK SHARP DOHME | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Mar, 2018
(7 years ago) | |
| US6524570 | MERCK SHARP DOHME | Polyethylene glycol modified interferon therapy |
Nov, 2016
(9 years ago) | |
|
US6461605 (Pediatric) | MERCK SHARP DOHME | Continuous low-dose cytokine infusion therapy |
May, 2017
(8 years ago) | |
Drugs and Companies using RIBAVIRIN ingredient
Market Authorisation Date: 03 June, 1998
Dosage: CAPSULE
How can I launch a generic of REBETOL before it's drug patent expiration?
More Information on Dosage
REBETOL family patents
21. Spectracef patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5958915 | VANSEN PHARMA | Antibacterial composition for oral administration |
Oct, 2016
(9 years ago) | |
Drugs and Companies using CEFDITOREN PIVOXIL ingredient
Market Authorisation Date: 29 August, 2001
Dosage: TABLET
More Information on Dosage
SPECTRACEF family patents
22. Striverdi Respimat patent expiration
Treatment: Treatment of chronic obstructive pulmonary disease (copd), chronic bronchitis or emphysema
STRIVERDI RESPIMAT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7491719 | BOEHRINGER INGELHEIM | Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments |
Nov, 2023
(2 years ago) | |
| US7056916 | BOEHRINGER INGELHEIM | Medicaments for the treatment of chronic obstructive pulmonary disease |
Dec, 2023
(2 years ago) | |
| US7220742 | BOEHRINGER INGELHEIM | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
May, 2025
(7 months ago) | |
| US7727984 | BOEHRINGER INGELHEIM | Medicaments for the treatment of chronic obstructive pulmonary disease |
Jan, 2027
(1 year, 9 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6726124 | BOEHRINGER INGELHEIM | Device for producing high pressure in a fluid in miniature |
Oct, 2016
(9 years ago) | |
| US7988001 | BOEHRINGER INGELHEIM | Container provided with a pressure equalization opening |
Aug, 2021
(4 years ago) | |
| US6176442 | BOEHRINGER INGELHEIM | Device for mounting a component exposed to a pressurized fluid |
Oct, 2016
(9 years ago) | |
| US7802568 | BOEHRINGER INGELHEIM | Cartridge for a liquid |
Feb, 2019
(6 years ago) | |
| US7104470 | BOEHRINGER INGELHEIM | Device for producing high pressure in a fluid in miniature |
Oct, 2016
(9 years ago) | |
| US8044046 | BOEHRINGER INGELHEIM | Medicaments for the treatment of chronic obstructive pulmonary disease |
Nov, 2023
(2 years ago) | |
| US6988496 | BOEHRINGER INGELHEIM | Cartridge for a liquid |
Feb, 2020
(5 years ago) | |
| US7246615 | BOEHRINGER INGELHEIM | Atomising nozzle and filter and spray generating device |
May, 2016
(9 years ago) | |
| US6846413 | BOEHRINGER INGELHEIM | Microstructured filter |
Aug, 2018
(7 years ago) | |
| US6977042 | BOEHRINGER INGELHEIM | Microstructured filter |
Aug, 2018
(7 years ago) | |
| US6149054 | BOEHRINGER INGELHEIM | Mechanical counter for a metering apparatus |
Dec, 2016
(9 years ago) | |
| US5964416 | BOEHRINGER INGELHEIM | Device for producing high pressure in a fluid in miniature |
Oct, 2016
(9 years ago) | |
| US6453795 | BOEHRINGER INGELHEIM | Locking mechanism for a spring-actuated device |
Dec, 2016
(9 years ago) | |
| US7786111 | BOEHRINGER INGELHEIM | Medicaments for the treatment of chronic obstructive pulmonary disease |
Nov, 2023
(2 years ago) | |
| US7396341 | BOEHRINGER INGELHEIM | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
Oct, 2026
(8 months from now) | |
| US9027967 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2027
(1 year, 2 months from now) | |
| US8034809 | BOEHRINGER INGELHEIM | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
May, 2025
(7 months ago) | |
| US7284474 | BOEHRINGER INGELHEIM | Piston-pumping system having o-ring seal properties |
Aug, 2024
(1 year, 4 months ago) | |
| US7837235 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2028
(2 years from now) | |
| US8733341 | BOEHRINGER INGELHEIM | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
Oct, 2030
(4 years from now) | |
| US7896264 | BOEHRINGER INGELHEIM | Microstructured high pressure nozzle with built-in filter function |
May, 2025
(7 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2019 |
Drugs and Companies using OLODATEROL HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2018
Market Authorisation Date: 31 July, 2014
Dosage: SPRAY, METERED
More Information on Dosage
STRIVERDI RESPIMAT family patents
23. Sunosi patent expiration
Treatment: To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa); Treatment of excessive daytime sleepiness in a breast-feeding pa...
SUNOSI IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12384743 | AXSOME MALTA | NA |
Nov, 2038
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8440715 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2031
(5 years from now) | |
| US12209059 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2026
(4 months from now) | |
| US12390419 | AXSOME MALTA | NA |
Sep, 2037
(11 years from now) | |
| US12090126 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US11753368 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2026
(4 months from now) | |
| US11998639 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(11 years from now) | |
| US12263145 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US12318362 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11969404 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US12194016 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US10940133 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11771666 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US10512609 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(11 years from now) | |
| US11779554 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US10351517 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2026
(4 months from now) | |
| US12036194 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US11560354 | AXSOME MALTA | Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof |
Mar, 2039
(13 years from now) | |
| US11160779 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11771667 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US8877806 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2026
(4 months from now) | |
| US12064411 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US11793776 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US10959976 | AXSOME MALTA | Methods and compositions for treating excessive sleepiness |
Jun, 2038
(12 years from now) | |
| US10912754 | AXSOME MALTA | Methods and compositions for treating excessive sleepiness |
Jun, 2038
(12 years from now) | |
| US11648232 | AXSOME MALTA | Methods and compositions for treating excessive sleepiness |
Jun, 2038
(12 years from now) | |
| US11865098 | AXSOME MALTA | Methods and compositions for treating excessive sleepiness |
Jun, 2038
(12 years from now) | |
| US11839599 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11839598 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11850227 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11850228 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11857528 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11872203 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US11872204 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US11986454 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US12005036 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US11850226 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11986455 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US12102609 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US11439597 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(11 years from now) | |
| US10195151 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(11 years from now) | |
| US9604917 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2026
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 17, 2024 |
| Orphan Drug Exclusivity(ODE-254) | Jun 17, 2026 |
Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient
NCE-1 date: 18 June, 2023
Market Authorisation Date: 17 June, 2019
Dosage: TABLET
How can I launch a generic of SUNOSI before it's drug patent expiration?
More Information on Dosage
SUNOSI family patents
24. Surfaxin patent expiration
Treatment: Prevention of respiratory distress (rds) in premature infants
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5407914 | LEES PHARM HK | Pulmonary surfactant protein and related polypeptides |
Nov, 2013
(12 years ago) | |
Drugs and Companies using LUCINACTANT ingredient
Market Authorisation Date: 06 March, 2012
Dosage: SUSPENSION
More Information on Dosage
SURFAXIN family patents
25. Tudorza Pressair patent expiration
Treatment: Maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd); Maintenance treatment of chronic obstructive pulmonary disease (copd); Treatment of a
TUDORZA PRESSAIR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE46417 | COVIS | Quinuclidine derivatives and their use as muscarinic M3 receptor ligands |
Feb, 2025
(10 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10034867 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(5 years ago) | |
| US9056100 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(5 years ago) | |
| US9333195 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(5 years ago) | |
| US5840279 | COVIS | Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments |
Jun, 2016
(9 years ago) | |
| US6750226 | COVIS | Quinuclidine derivatives and their use as muscarinic M3 receptor ligands |
Sep, 2020
(5 years ago) | |
| US7078412 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(5 years ago) | |
| US10588895 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(5 years ago) | |
| US6071498 | COVIS | Inhaler for powdered medicaments |
Jun, 2016
(9 years ago) | |
| US6681768 | COVIS | Powder formulation disintegrating system and method for dry powder inhalers |
Aug, 2022
(3 years ago) | |
| US10085974 | COVIS | Dosage and formulation |
Mar, 2029
(3 years from now) | |
| US11000517 | COVIS | Dosage and formulation |
Mar, 2029
(3 years from now) | |
| US8051851 | COVIS | Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler |
Apr, 2027
(1 year, 3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2017 |
| M(M-256) | Mar 29, 2022 |
Drugs and Companies using ACLIDINIUM BROMIDE ingredient
NCE-1 date: 23 July, 2016
Market Authorisation Date: 23 July, 2012
Dosage: POWDER, METERED
More Information on Dosage
TUDORZA PRESSAIR family patents
26. Yupelri patent expiration
Treatment: For the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7585879 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(10 months ago) | |
| US11858898 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(4 years from now) | |
| US10550081 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(4 years from now) | |
| US9765028 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(4 years from now) | |
| US8541451 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Aug, 2031
(5 years from now) | |
| US7288657 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Oct, 2028
(2 years from now) | |
| US7910608 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(10 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11484531 | MYLAN IRELAND LTD | Methods for treating chronic obstructive pulmonary disease |
Oct, 2039
(13 years from now) | |
| US12285417 | MYLAN IRELAND LTD | Methods for treating chronic obstructive pulmonary disease |
Aug, 2039
(13 years from now) | |
| US7491736 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(10 months ago) | |
| US7521041 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(10 months ago) | |
| US10106503 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(10 months ago) | |
| US10343995 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(10 months ago) | |
| US8053448 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(10 months ago) | |
| US12048692 | MYLAN IRELAND LTD | Methods for treating chronic obstructive pulmonary disease |
Aug, 2039
(13 years from now) | |
| US11008289 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(4 years from now) | |
| US11247969 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(10 months ago) | |
| US8273894 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(10 months ago) | |
| US7550595 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(10 months ago) | |
| US11691948 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(4 years from now) | |
| US8034946 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(10 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 09, 2023 |
Drugs and Companies using REVEFENACIN ingredient
NCE-1 date: 09 November, 2022
Market Authorisation Date: 09 November, 2018
Dosage: SOLUTION
How can I launch a generic of YUPELRI before it's drug patent expiration?
More Information on Dosage
YUPELRI family patents